Fourty-three (42–47, 49–71, 73, 78, 85, 98, 116, 117, 118, 125, 131–135, 148, 149) out of the 132 studies (33, 35–41, 48, 72, 74–77, 79–84, 86–97, 99–115, 119–124, 126–130, 133, 136–147, 150–164) selected were conducted in humans, and, in 89 manuscripts (33–164>, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116–118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143–147, 149, 150–164) selected were conducted in humans, and, in 89 manuscripts (33–164), animal models were applied for the study of the therapeutic effects of the administration of hMSCs for the treatment of immune-related diseases. Among the articles that used animal models, 80 used mice (33–41, 48, 72, 74–77, 79–84, 86, 87, 89–94, 96, 99–107, 109, 110, 113–115, 119–129, 133, 136–139, 141, 143–147, 150–164), six used rats (88, 95, 97, 130, 140, 142) and three used pigs (108, 111, 112) as the experimental model. The use of these different experimental models in the articles reviewed is graphically represented on Figure 4. It is important to notice that, in 29 (42–47, 49–71) out of the fourth-two studies conducted in humans, hMSCs were administered for the treatment of graft-versus-host disease following HSCT. In addition, in two human studies (52, 73), hMSCs were used for the treatment of hemophagocytic syndrome, in five studies (125, 131, 132, 134, 135) they were used for the treatment of multiple sclerosis and in two studies (116, 117) they were used for the treatment of Crohn's disease. The treatment of neuromyelitis optica (149), myasthenia gravis (148), ankylosing spondylitis (98), type II refractory celiac disease (118), systemic sclerosis (85) and type I diabetes mellitus (78) was conducted in humans in only one article each. The use of hMSCs for the treatment of immune-related diseases in human studies is graphically represented on Figure 4.